Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal

RR Griffiths, CA Sannerud, NA Ator and JV Brady

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.

This study examined in baboons various behavioral effects of zolpidem, a short-acting imidazopyridine hypnotic which has selectivity for subtypes of the benzodiazepine receptor. Intravenous drug self- injection was studied under a fixed-ratio 80- or 160-response schedule with a 3-hr timeout after each injection. Maximal rates of self- injection maintained by zolpidem (0.01-1 mg/kg) were consistently higher than those maintained by vehicle and the benzodiazepine hypnotic triazolam. Substitution of vehicle after about 2 weeks of zolpidem self- injection (7-8 mg/kg/day) resulted in a time-limited suppression of food pellet intake, indicating a drug withdrawal effect. In a drug discrimination study, baboons were trained to discriminate either lorazepam (1.8 mg/kg p.o.) or pentobarbital (10 mg/kg p.o.) from the no- drug condition. Zolpidem (0.1-18 mg/kg p.o.) occasioned both lorazepam- and pentobarbital-appropriate responding (greater than 80%) in a dose- dependent manner. In a final experiment, zolpidem (3.2 or 5.6 mg/kg i.m.) produced ataxia and sedation that progressively decreased over 7 consecutive days of administration. The withdrawal, discriminative stimulus effects and tolerance shown with zolpidem were similar to those shown previously with benzodiazepines under similar conditions. The rates of self-injection of zolpidem were similar to those maintained by intermediate duration barbiturates (e.g., pentobarbital) and higher than those maintained by 11 benzodiazepines studied previously under similar conditions. Further research on the reinforcing effects of zolpidem may provide useful insights into mechanisms underlying the maintenance of behavior by compounds acting through the benzodiazepine receptor.

Volume 260, Issue 3, pp. 1199-1208, 03/01/1992
Copyright © 1992 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				L. P. Carter, R. R. Griffiths, P. E. Suess, J. H. Casada, C. L. Wallace, and J. D. Roache Relative Abuse Liability of Indiplon and Triazolam in Humans: A Comparison of Psychomotor, Subjective, and Cognitive Effects J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 749 - 759. [Abstract] [Full Text] [PDF]

				R. E. Petroski, J. E. Pomeroy, R. Das, H. Bowman, W. Yang, A. P. Chen, and A. C. Foster Indiplon Is a High-Affinity Positive Allosteric Modulator with Selectivity for {alpha}1 Subunit-Containing GABAA Receptors J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 369 - 377. [Abstract] [Full Text] [PDF]

				J. K. Rowlett, R. D. Spealman, and S. Lelas Discriminative Stimulus Effects of Zolpidem in Squirrel Monkeys: Comparison with Conventional Benzodiazepines and Sedative-Hypnotics J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1233 - 1241. [Abstract] [Full Text]

				N. A. Ator and R. R. Griffiths Drug Discrimination Analysis of Partial Agonists at the Benzodiazepine Site. I. Differential Effects of U-78875 Across Training Conditions in Baboons and Rats J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1434 - 1446. [Abstract] [Full Text]

				J. M. Fahey, G. A. Pritchard, J. M. Grassi, J. S. Pratt, R. I. Shader, and D. J. Greenblatt In situ hybridization histochemistry as a method to assess GABAAreceptor subunit mRNA expression following chronic alprazolam administration J Psychopharmacol, May 1, 1999; 13(3): 211 - 218. [Abstract] [PDF]

				G. Darcourt, D. Pringuey, D. Salliere, and J. Lavoisy The safety and tolerability of zolpidem -- an update J Psychopharmacol, January 1, 1999; 13(1): 81 - 93. [Abstract] [PDF]

				E. M. Weerts, N. A. Ator, D. M. Grech, and R. R. Griffiths Zolpidem Physical Dependence Assessed Across Increasing Doses Under a Once-Daily Dosing Regimen in Baboons J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 41 - 53. [Abstract] [Full Text]

				A. Ravishankar and T. Carnwath Zolpidem tolerance and dependence --two case reports J Psychopharmacol, January 1, 1998; 12(1): 103 - 104. [Abstract] [PDF]

				N. A. Ator and R. R. Griffiths Selectivity in the Generalization Profile in Baboons Trained to Discriminate Lorazepam: Benzodiazepines, Barbiturates and Other Sedative/Anxiolytics J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1442 - 1457. [Abstract] [Full Text]

				J. K. Rowlett and W. L. Woolverton Discriminative Stimulus Effects of Zolpidem in Pentobarbital-Trained Subjects: I. Comparison with Triazolam in Rhesus Monkeys and Rats J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 162 - 173. [Abstract] [Full Text]

				C. R. Rush, S. Madakasira, N. H. Goldman, W. L. Woolverton, and J. K. Rowlett Discriminative Stimulus Effects of Zolpidem in Pentobarbital-Trained Subjects: II. Comparison with Triazolam and Caffeine in Humans J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 174 - 188. [Abstract] [Full Text]

				{blacktriangledown}Zolpidem - a hypnotic with a difference ? DTB, May 1, 1995; 33(5): 37 - 39. [Abstract] [Full Text] [PDF]

				C. A. Gericke and A. C. Ludolph Chronic Abuse of Zolpidem JAMA, December 14, 1994; 272(22): 1721 - 1722. [Abstract] [PDF]

				A. J. Goudie and M. J. Leathley Assessment of the dependence potential of the potent high-efficacy 5-HT1A agonist S-14506 in rats J Psychopharmacol, January 1, 1994; 8(4): 213 - 221. [Abstract] [PDF]